Highest-materiality recent filing
Kalaris Therapeutics announces director resignation and election of Laurie Keating
Morana Jovan-Embiricos resigned from board and audit committee effective July 3, 2026; no disagreement with company.
Kalaris Therapeutics holds 2026 annual meeting; all proposals pass
Elected Napoleone Ferrara, David Hallal, Leone Patterson as Class III directors (three-year terms).
Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients
Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).
CFO Matthew Gall resigns; CAO Brett Hagen takes over as principal financial officer
Matthew Gall resigned as CFO, effective April 14, 2026.
Kalaris reports positive Phase 1a TH103 data, $118M cash, net loss $43.4M in 2025
Phase 1a in nAMD showed mean 10-letter BCVA gain, 129µm CST improvement, ~95% intraretinal fluid reduction.
Kalaris releases corporate presentation with TH103 trial updates but no specific figures disclosed
Presentation includes timelines for reporting Phase 1b/2 data of TH103 and plans to initiate Phase 3; no dates or numbers given in filing.
Kalaris Therapeutics raises $50M in oversubscribed private placement; cash runway into Q3 2027
Raised ~$50M gross via 4.2M shares at $10.00/share and 800K pre-funded warrants at $9.9999.
Kalaris Therapeutics reports positive Phase 1a data for TH103 in nAMD; accelerates development
Mean 10-letter BCVA gain and 129 µm CST improvement at Month 1 across all dose levels (0.5–2.5 mg).
Kalaris Q3 net loss narrows to $11.9M; cash $77M; Phase 1a data on track for year-end
Phase 1a SAD trial initial clinical data (safety, efficacy, PK) expected by year end 2025.
Kalaris Therapeutics appoints Matthew Gall as CFO effective November 3, 2025
Matthew Gall appointed CFO and Treasurer effective Nov 3, 2025; succeeds Brett Hagan as principal financial officer.
Kalaris Q2 2025 net loss $11.4M; Phase 1 TH103 data expected Q4 2025
Net loss $11.4M ($0.61/shr) vs $5.7M ($4.26/shr) in Q2 2024; no revenue in either period.
Kalaris Therapeutics stockholders elect two Class II directors, ratify Deloitte as auditor
Srinivas Akkaraju and Andrew Oxtoby elected as Class II directors for three-year terms expiring 2028.
Kalaris sets Aug 12, 2025 annual meeting; stockholder proposals due June 30
2025 annual meeting scheduled for August 12, 2025; postponed from typical anniversary date.
Kalaris Q1 net loss $10.2M ($2.52/shr); cash $101M; TH103 Phase 1 data expected Q4 2025
Net loss of $10.2M for Q1 2025 vs $3.4M for Q1 2024; diluted EPS loss $2.52.
Kalaris Therapeutics enters new CEO employment agreement with severance benefits; CAO severance set
CEO Oxtoby's new base salary is $569,100; target bonus up to 55% of base salary.
Kalaris Therapeutics appoints Leone Patterson to Board as Audit Committee Chair
Leone Patterson elected Class III director effective April 3, 2025; term expires at 2026 annual meeting.
AlloVir completes reverse merger with Legacy Kalaris; ticker changes to KLRS on Nasdaq
Post-merger combined company focuses on retinal disease therapeutics; TH103 is lead candidate.
AlloVir shareholders approve merger with Kalaris; combined co to trade as KLRS
Stockholders voted to approve merger: 3,543,715 for, 368,843 against, 282 abstain out of 3,912,840 votes cast.
AlloVir effects 1-for-23 reverse stock split effective Jan 15, 2025
Reverse split at 1-for-23 ratio, approved by board on Jan 9 after stockholder vote.
AlloVir shareholders approve reverse stock split ratio range 1:15–1:35; board to set exact ratio
96,216,120 votes for, 12,082,172 against, 303,036 abstain; adjournment not needed.
AlloVir announces 1-for-23 reverse stock split effective Jan 15, 2025
Board approved 1-for-23 reverse stock split; effective 4:05 PM ET Jan 15, 2025.
CEO Diana Brainard departs; President/CFO Vikas Sinha named CEO effective Dec 19, 2024
Diana Brainard resigned as CEO and director effective Dec 19; no disagreement with company on operations, policies, or practices.
AlloVir acquires Kalaris; pre-merger AlloVir stockholders own ~25.05%, Kalaris ~74.95% on fully diluted basis, subject to net cash adjustments.
AlloVir terminates Waltham lease, pays $7M early termination fee
Terminated lease with BP Bay Colony for 78,541 sq ft at 1100 Winter Street, Waltham, effective June 30, 2024.
AlloVir terminates Waltham sublease, agrees to pay $5.7M termination fee
Sublease terminated effective June 30, 2024; originally set to expire July 31, 2028.
Elected Juan Vera (77.7M for, 4.2M withhold), Morana Jovan-Embiricos (76.2M for, 5.8M withhold), Derek Adams (76.2M for, 5.7M withhold) as Class I directors.
AlloVir approves $100K transaction bonuses for CEO, CFO, GC contingent on 2024 change of control
Board approved $100K cash bonuses to CEO Diana Brainard, President/CFO Vikas Sinha, and GC Edward Miller.
AlloVir receives Nasdaq notice of non-compliance; bid price below $1.00 for 30 days
Received Nasdaq letter on Feb 9, 2024, for bid price < $1.00 over 30 consecutive business days.
AlloVir reduces workforce by ~95%; expects $13M in severance charges
Board approved cutting ~95% of employees to preserve capital after discontinuing three global Phase 3 posoleucel studies (announced Dec 22, 2023).
AlloVir discontinues all three Phase 3 posoleucel trials after DSMB futility analyses
Three Phase 3 trials for prevention, hemorrhagic cystitis, and adenovirus stopped after separate DSMBs deemed each unlikely to meet primary endpoints.
AlloVir Q3 net loss $44.3M ($0.39/sh); cash $213.3M funds trials to H2 2024 data
Net loss $44.3M vs $42.1M in Q3 2022; diluted EPS loss $0.39 vs $0.50.
AlloVir Q2 net loss $45.3M; cash $246.5M; three Phase 3 trials on track for H2 2024 data
Net loss of $45.3M ($0.48 per share) vs $44.6M ($0.69) in Q2 2022.
AlloVir prices public offering of 20M shares at $3.75/share for $75M gross
Priced underwritten public offering of 20,000,000 shares at $3.75 per share; gross proceeds of $75.0M.
AlloVir suspends ATM equity program; terminates prospectus supplement with SVB
Notified SVB Securities on June 21, 2023 to suspend and terminate the ATM prospectus supplement.
AlloVir stockholder vote approves doubling authorized common shares to 300M
Charter amendment filed May 15 increases authorized common from 150M to 300M shares.
AlloVir reports Q1 net loss $41.2M; Phase 3 posoleucel trials on track for 2024
Net loss of $41.2M ($0.44/share) vs $43.9M ($0.69/share) in Q1 2022.
AlloVir appoints Derek Adams to board; Ansbert Gadicke retires
Derek Adams, Ph.D. appointed to Board effective March 1, 2023, filling vacancy from Ansbert Gadicke's retirement.
AlloVir reports FY2022 net loss of $168.7M and positive Phase 2 posoleucel data in kidney transplant
FY2022 net loss $168.7M ($2.20/share); R&D spend $118.9M; cash & securities $233.8M as of Dec 31, 2022.
AlloVir plans Phase 3 posoleucel enrollment completion in 2023; $234M cash
Cash balance $234M as of Dec 31, 2022; FY 2023 operating expenses guided $150M-$170M.
AlloVir announces resignation of Chief Commercial Officer Jeroen van Beek effective Nov 23
EVP and CCO Jeroen van Beek resigns Nov 23, 2022 to pursue new opportunities; will consult through Dec 31.
AlloVir reports Q3 net loss $42.1M; cash $264.1M, advancing Phase 3 posoleucel trials
Net loss of $42.1M ($0.50/sh) in Q3 2022 vs $45.5M ($0.72) in Q3 2021.
AlloVir Q2 net loss $44.6M; $126.5M July offering extends cash runway for Phase 3 trials
Net loss $44.6M ($0.69/sh) vs $37.6M ($0.60/sh) in Q2 2021; R&D expense rose to $31.4M.
AlloVir raises $126.6M in registered direct offering at $4.61/share for Phase 3 trials
Sold 27.46M shares at $4.61 each; gross proceeds ~$126.6M.
AlloVir stockholders elect Sinha and Brenner as Class II directors; ratify Deloitte
Vikas Sinha elected with 47,229,880 for, 4,036,755 withhold, 10,745,678 broker non-votes.
AlloVir Q1 net loss $43.9M; advances posoleucel to Phase 3 multi-virus prevention
Net loss $43.9M ($0.69/share) vs $30.9M ($0.50) in Q1 2021; R&D spend $29.1M.
AlloVir appoints Shawn Tomasello to board; co-founder John Wilson to retire
Shawn Tomasello appointed to Board of Directors effective March 29, 2022, serving as Class III director until 2023 annual meeting.
AlloVir reports FY2021 net loss $172M; cash $248.1M; three Phase 3 trials advancing
Net loss $172.0M ($2.74/share) for 2021 vs. $69.8M in 2020; cash $248.1M at year-end.
AlloVir reports $248.1M cash at year-end 2021; JPM presentation ongoing
Unaudited cash, equivalents and marketable securities total $248.1M as of Dec 31, 2021.
AlloVir CMO Agustin Melian to depart at year-end; Richard Riese to lead clinical programs
CMO Agustin Melian, MD, leaves AlloVir at end of 2021 after two and a half years.
No end-organ viral disease observed in 23 high-risk allo-HCT patients receiving posoleucel.
On July 3, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board elected Laurie Keating to serve as a member of the Board, effective as of August 1, 2026.
On July 3, 2026, Morana Jovan-Embiricos, Ph.D., notified Kalaris Therapeutics, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.
On April 3, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”), the Board elected Leone Patterson to serve as a member of the Board, effective immediately.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
David Hallal was appointed Chair of the Board.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
the Board was reconstituted as follows: (i) David Hallal and Morana Jovan-Embiricos, Ph.D. (designated by AlloVir), (ii) Andrew Oxtoby, Anthony Adamis, Srinivas Akkaraju, M.D., Ph.D., Michael Dybbs, Ph.D., Napoleone Ferrara, M.D., and Samir Patel, M.D.
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
at the Effective Time, Vikas Sinha, Derek Adams, Ph.D., Malcom Brenner, M.D., Ph.D., Jeffrey S. Bornstein, Shawn Tomasello and Juan Vera, M.D., resigned from the Board
Max materiality 0.95 · Median 0.60 · Most common event other_material